| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| KPRXKiora Pharmaceuticals, Inc. | 8.05M | 2.19 | 2.52 | 22.47% | -38.12% | 100% | 0.00 | |
| KALAKALA BIO, Inc. | 16.74M | 0.60 | -0.09 | -141.11% | -388.29% | 2.62 | ||
| CLSDClearside Biomedical, Inc. | 5.81M | 1.11 | -0.16 | -79.77% | -7.81% | |||
| OTLKOutlook Therapeutics, Inc. | 33.47M | 0.52 | -0.29 | -25.93% | ||||
| ADVMAdverum Biotechnologies, Inc. | 96.26M | 4.36 | -0.66 | -72.22% | -130.93% | -189.84% | 1.30 | |
| IRDOpus Genetics, Inc. | 143.45M | 2.08 | -0.97 | -42.3% | -466.09% | -11.43% | ||
| SKYESkye Bioscience, Inc. | 30.87M | 0.96 | -1.32 | -156.01% | 0.01 | |||
| ALDXAldeyra Therapeutics, Inc. | 265.32M | 4.41 | -4.69 | -87.71% | 0.22 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 2.32M | 1.46M | 1.85M | 1.61M | 250K | 0 | 7.5M | 0 | 3.6M | 1M |
| Revenue Growth % | 3.05% | -0.37% | 0.27% | -0.13% | -0.84% | -1% | - | -1% | - | -0.72% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 4.16M | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 2.32M | 0 | 0 | 0 | 0 | -4.16M | 7.5M | 0 | 3.6M | 1M |
| Gross Margin % | 1% | - | - | - | - | - | 1% | - | 1% | 1% |
| Gross Profit Growth % | 3.05% | -1% | - | - | - | - | 2.8% | -1% | - | -0.72% |
| Operating Expenses | 50.14M | 116.74M | 60.7M | 79.69M | 68.8M | 113.79M | 153.62M | 157.13M | 132.54M | 140.16M |
| OpEx % of Revenue | 21.62% | 80.23% | 32.83% | 49.44% | 275.18% | - | 20.48% | - | 36.82% | 140.16% |
| Selling, General & Admin | 22.11M | 24.36M | 20.86M | 24.56M | 28.38M | 44.64M | 64.44M | 57.86M | 55.06M | 63.12M |
| SG&A % of Revenue | 9.53% | 16.74% | 11.28% | 15.24% | 113.5% | - | 8.59% | - | 15.29% | 63.12% |
| Research & Development | 25.46M | 31.67M | 39.84M | 50.13M | 40.42M | 73.31M | 89.18M | 99.28M | 77.49M | 77.04M |
| R&D % of Revenue | 10.98% | 21.77% | 21.55% | 31.1% | 161.68% | - | 11.89% | - | 21.52% | 77.04% |
| Other Operating Expenses | 2.57M | 60.71M | 0 | 5M | 0 | -4.16M | 0 | 0 | 0 | 0 |
| Operating Income | -47.82M | -115.28M | -58.85M | -78.08M | -68.55M | -117.95M | -146.12M | -157.13M | -128.94M | -139.16M |
| Operating Margin % | -20.62% | -79.23% | -31.83% | -48.44% | -274.18% | - | -19.48% | - | -35.82% | -139.16% |
| Operating Income Growth % | -0.96% | -1.41% | 0.49% | -0.33% | 0.12% | -0.72% | -0.24% | -0.08% | 0.18% | -0.08% |
| EBITDA | -47.01M | -113.68M | -56.75M | -76.33M | -66.97M | -113.79M | -141.48M | -150.61M | -123.3M | -135.51M |
| EBITDA Margin % | -20.27% | -78.13% | -30.69% | -47.35% | -267.89% | - | -18.86% | - | -34.25% | -135.51% |
| EBITDA Growth % | -0.94% | -1.42% | 0.5% | -0.35% | 0.12% | -0.7% | -0.24% | -0.06% | 0.18% | -0.1% |
| D&A (Non-Cash Add-back) | 812K | 1.6M | 2.1M | 1.75M | 1.57M | 4.16M | 4.64M | 6.53M | 5.64M | 3.65M |
| EBIT | -45.25M | -54.57M | -58.85M | -73.08M | -68.55M | -116.39M | -146.12M | -157.13M | -128.94M | -139.16M |
| Net Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 370K | 762K | 2.7M | 4.2M | 4.06M | 1.56M | 582K | 2.67M | 5.75M | 8.23M |
| Pretax Income | -47.45M | -114.52M | -56.15M | -73.88M | -64.49M | -116.39M | -145.54M | -154.46M | -123.19M | -130.93M |
| Pretax Margin % | -20.46% | -78.71% | -30.37% | -45.83% | -257.94% | - | -19.41% | - | -34.22% | -130.93% |
| Income Tax | 0 | -775K | 0 | -1.25M | 0 | 1.11M | 0 | 74K | -1.08M | 0 |
| Effective Tax Rate % | 1% | 0.99% | 1% | 0.98% | 1% | 1.01% | 1% | 1% | 0.99% | 1% |
| Net Income | -47.45M | -113.75M | -56.15M | -72.63M | -64.49M | -117.51M | -145.54M | -154.54M | -122.12M | -130.93M |
| Net Margin % | -20.46% | -78.18% | -30.37% | -45.05% | -257.94% | - | -19.41% | - | -33.92% | -130.93% |
| Net Income Growth % | -0.87% | -1.4% | 0.51% | -0.29% | 0.11% | -0.82% | -0.24% | -0.06% | 0.21% | -0.07% |
| Net Income (Continuing) | -47.45M | -113.75M | -56.15M | -72.63M | -64.49M | -117.51M | -145.54M | -154.54M | -122.12M | -130.93M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.84 | -3.14 | -1.29 | -1.18 | -0.87 | -1.26 | -1.48 | -2.67 | -2.02 | -6.62 |
| EPS Growth % | -0.64% | -0.71% | 0.59% | 0.09% | 0.26% | -0.45% | -0.17% | -0.8% | 0.24% | -2.28% |
| EPS (Basic) | -1.86 | -3.14 | -1.29 | -1.18 | -0.87 | -1.26 | -1.48 | -2.67 | -2.02 | -6.62 |
| Diluted Shares Outstanding | 25.86M | 36.25M | 43.66M | 61.38M | 73.8M | 93.31M | 98.36M | 57.98M | 57.98M | 19.78M |
| Basic Shares Outstanding | 25.48M | 36.25M | 43.66M | 61.38M | 73.8M | 93.23M | 98.36M | 57.98M | 57.98M | 19.78M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 260.99M | 225.27M | 193.74M | 208.75M | 175.87M | 434.44M | 317.14M | 190.59M | 102.77M | 131.3M |
| Cash & Short-Term Investments | 259.08M | 222.17M | 190.49M | 205.08M | 166.03M | 429.73M | 305.19M | 185.59M | 96.53M | 125.69M |
| Cash Only | 259.08M | 222.17M | 70.52M | 154.95M | 65.9M | 62.42M | 34.2M | 68.43M | 75M | 60.65M |
| Short-Term Investments | 0 | 0 | 119.97M | 50.13M | 100.14M | 367.31M | 270.99M | 117.16M | 21.53M | 65.04M |
| Accounts Receivable | 449K | 886K | 0 | 0 | 0 | 0 | 5.71M | 0 | 0 | 0 |
| Days Sales Outstanding | 70.67 | 222.26 | - | - | - | - | 277.84 | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 3.26M | 3.67M | 9.84M | 0 | 6.25M | 5.01M | 6.25M | 5.61M |
| Total Non-Current Assets | 3.33M | 9.31M | 8.16M | 4.74M | 46.86M | 48.13M | 122.58M | 117.78M | 52.99M | 48.54M |
| Property, Plant & Equipment | 3.19M | 4.17M | 3.02M | 3.59M | 45.85M | 47.1M | 119.06M | 113.86M | 49.79M | 45.22M |
| Fixed Asset Turnover | 0.73x | 0.35x | 0.61x | 0.45x | 0.01x | - | 0.06x | - | 0.07x | 0.02x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 5M | 5M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 999K | 999K | 0 | 3.27M | 2.5M | 0 | 0 |
| Other Non-Current Assets | 140K | 140K | 140K | 156K | 11K | 1.03M | 250K | 1.41M | 3.21M | 3.32M |
| Total Assets | 264.32M | 234.58M | 201.91M | 213.5M | 222.73M | 482.57M | 439.73M | 308.37M | 155.77M | 179.84M |
| Asset Turnover | 0.01x | 0.01x | 0.01x | 0.01x | 0.00x | - | 0.02x | - | 0.02x | 0.01x |
| Asset Growth % | 0.63% | -0.11% | -0.14% | 0.06% | 0.04% | 1.17% | -0.09% | -0.3% | -0.49% | 0.15% |
| Total Current Liabilities | 6.57M | 9.9M | 10.67M | 10.72M | 19.41M | 20.87M | 21.32M | 32.25M | 19.98M | 22.9M |
| Accounts Payable | 605K | 1.47M | 1.73M | 1.71M | 4.1M | 2.81M | 1.39M | 2.24M | 1.92M | 1.61M |
| Days Payables Outstanding | - | - | - | - | - | 246.67 | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 4.13M | 0 | 1.89M | 0 | 0 | 0 |
| Deferred Revenue (Current) | 883K | 1000K | 1000K | -100K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 3.17M | 4M | 4.83M | 6.07M | 7.12M | 9.63M | 7.52M | 9.13M | 8.77M | 5.96M |
| Current Ratio | 39.70x | 22.76x | 18.15x | 19.48x | 9.06x | 20.82x | 14.88x | 5.91x | 5.14x | 5.73x |
| Quick Ratio | 39.70x | 22.76x | 18.15x | 19.48x | 9.06x | 20.82x | 14.88x | 5.91x | 5.14x | 5.73x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 5.15M | 9.09M | 7.2M | 1.61M | 28.36M | 27.35M | 102.22M | 94.61M | 68.56M | 86.23M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 100K | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 28.21M | 26.23M | 101.11M | 93.56M | 68.56M | 86.04M |
| Deferred Tax Liabilities | 0 | 1.25M | 1.25M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 447K | 738K | 703K | 1.41M | 48K | 1.11M | 1.11M | 1.05M | 0 | 192K |
| Total Liabilities | 11.73M | 18.98M | 17.88M | 12.33M | 47.77M | 48.22M | 123.54M | 126.85M | 88.55M | 109.13M |
| Total Debt | 0 | 0 | 400K | 300K | 32.45M | 30.71M | 102.99M | 106.8M | 74.04M | 91.7M |
| Net Debt | -259.08M | -222.17M | -70.12M | -154.65M | -33.45M | -31.72M | 68.8M | 38.37M | -959K | 31.05M |
| Debt / Equity | - | - | 0.00x | 0.00x | 0.19x | 0.07x | 0.33x | 0.59x | 1.10x | 1.30x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - | - | - | - |
| Total Equity | 252.59M | 215.6M | 184.03M | 201.17M | 174.96M | 434.35M | 316.19M | 181.52M | 67.22M | 70.71M |
| Equity Growth % | 0.69% | -0.15% | -0.15% | 0.09% | -0.13% | 1.48% | -0.27% | -0.43% | -0.63% | 0.05% |
| Book Value per Share | 9.77 | 5.95 | 4.21 | 3.28 | 2.37 | 4.65 | 3.21 | 3.13 | 1.16 | 3.57 |
| Total Shareholders' Equity | 252.59M | 215.6M | 184.03M | 201.17M | 174.96M | 434.35M | 316.19M | 181.52M | 67.22M | 70.71M |
| Common Stock | 3K | 4K | 5K | 6K | 7K | 10K | 10K | 10K | 1K | 2K |
| Retained Earnings | -84.17M | -197.91M | -254.06M | -320.54M | -385.03M | -502.54M | -648.08M | -802.61M | -936.02M | -1.07B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -11K | -7K | -963K | -799K | -725K | -261K | -714K | -1.53M | -473K | -407K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -35.34M | -38.37M | -45.42M | -53.96M | -49.17M | -79.29M | -107.83M | -108.09M | -90.9M | -92.46M |
| Operating CF Margin % | -15.24% | -26.37% | -24.57% | -33.48% | -196.68% | - | -14.38% | - | -25.25% | -92.46% |
| Operating CF Growth % | -5.26% | -0.09% | -0.18% | -0.19% | 0.09% | -0.61% | -0.36% | -0% | 0.16% | -0.02% |
| Net Income | -47.45M | -113.75M | -56.15M | -72.63M | -64.49M | -117.51M | -145.54M | -154.54M | -122.12M | -130.93M |
| Depreciation & Amortization | 812K | 1.6M | 2.1M | 1.75M | 1.57M | 4.16M | 4.64M | 6.53M | 5.64M | 3.65M |
| Stock-Based Compensation | 11.51M | 11.42M | 8.72M | 13.43M | 9.9M | 20.39M | 25.19M | 20.08M | 17.57M | 14.35M |
| Deferred Taxes | 801K | 60.71M | 593K | -1.25M | -1.27M | 863K | 3.83M | 0 | 0 | 0 |
| Other Non-Cash Items | 218K | 8K | 70K | 6.35M | 58K | 75K | -25K | -51K | 16.51M | 19.55M |
| Working Capital Changes | -1.22M | 1.64M | -756K | -1.62M | 5.06M | 12.73M | 4.06M | 19.89M | -8.51M | 911K |
| Change in Receivables | -6K | -437K | 886K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 1.2M | -1.11M | -29K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -312K | -111K | 333K | -67K | -650K | 1.58M | -1.61M | 845K | -369K | -262K |
| Cash from Investing | -41.57M | 38.77M | -122.2M | 69.44M | -68.07M | -280.17M | 78.71M | 141.72M | 96.88M | -41.89M |
| Capital Expenditures | -2.99M | -2.41M | -1.02M | -809K | -19.25M | -11.84M | -15.12M | -11.82M | -808K | -388K |
| CapEx % of Revenue | 1.29% | 1.66% | 0.55% | 0.5% | 76.99% | - | 2.02% | - | 0.22% | 0.39% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 38.77M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 138.86M | 556K | 16.75M | 69.95M | 28.19M | 355.99M | 2.4M | 607K | 69K | 120M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | -94K | 556K | 229K | -63K | 2.41M | 11.74M | 952K | 0 | -420K | 642K |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -38.33M | -40.78M | -46.44M | -54.77M | -68.42M | -91.14M | -122.95M | -119.91M | -91.71M | -92.85M |
| FCF Margin % | -16.53% | -28.03% | -25.11% | -33.98% | -273.67% | - | -16.39% | - | -25.48% | -92.85% |
| FCF Growth % | -4.82% | -0.06% | -0.14% | -0.18% | -0.25% | -0.33% | -0.35% | 0.02% | 0.24% | -0.01% |
| FCF per Share | -1.48 | -1.13 | -1.06 | -0.89 | -0.93 | -0.98 | -1.25 | -2.07 | -1.58 | -4.69 |
| FCF Conversion (FCF/Net Income) | 0.74x | 0.34x | 0.81x | 0.74x | 0.76x | 0.67x | 0.74x | 0.70x | 0.74x | 0.71x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -23.6% | -48.59% | -28.1% | -37.71% | -34.29% | -38.57% | -38.78% | -62.1% | -98.19% | -189.84% |
| Return on Invested Capital (ROIC) | - | - | -82.24% | -73.01% | -54.68% | -32.51% | -27.83% | -38.97% | -67.59% | -124.23% |
| Gross Margin | 100% | - | - | - | - | - | 100% | - | 100% | 100% |
| Net Margin | -2046.27% | -7817.66% | -3036.61% | -4505.4% | -25794.4% | - | -1940.53% | - | -3392.11% | -13092.7% |
| Debt / Equity | - | - | 0.00x | 0.00x | 0.19x | 0.07x | 0.33x | 0.59x | 1.10x | 1.30x |
| FCF Conversion | 0.74x | 0.34x | 0.81x | 0.74x | 0.76x | 0.67x | 0.74x | 0.70x | 0.74x | 0.71x |
| Revenue Growth | 305.42% | -37.26% | 27.08% | -12.82% | -84.49% | -100% | - | -100% | - | -72.22% |
| 2024 | |
|---|---|
| Reportable | 1M |
| Reportable Growth | - |
Adverum Biotechnologies, Inc. (ADVM) reported $1.0M in revenue for fiscal year 2024. This represents a 3233% increase from $0.0M in 2012.
Adverum Biotechnologies, Inc. (ADVM) saw revenue decline by 72.2% over the past year.
Adverum Biotechnologies, Inc. (ADVM) reported a net loss of $204.4M for fiscal year 2024.
Adverum Biotechnologies, Inc. (ADVM) has a return on equity (ROE) of -189.8%. Negative ROE indicates the company is unprofitable.
Adverum Biotechnologies, Inc. (ADVM) had negative free cash flow of $138.4M in fiscal year 2024, likely due to heavy capital investments.